Our findings demonstrated that miR-145 function as a tumor suppressor in NPC development and progression through targeting FSCN1, suggesting that miR-145/FSCN1 pathway may sever as a potential novel therapeutic target for patients with NPC. Here, FSCN1 is linked to nasopharyngeal carcinoma.